Patents by Inventor Guiying Cui

Guiying Cui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
    Patent number: 11844785
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Grant
    Filed: May 5, 2021
    Date of Patent: December 19, 2023
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui
  • 2-amino-N'-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
    Patent number: 11116736
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 14, 2021
    Assignees: Emory University, Bar-Ilan University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide Compounds for the Management of CFTR Protein Mediated Diseases
    Publication number: 20210260044
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Application
    Filed: May 5, 2021
    Publication date: August 26, 2021
    Inventors: Nael McCarty, Guiying Cui
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
    Patent number: 11020379
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 1, 2021
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui
  • Adjusting device for a vehicle seat
    Patent number: 10981472
    Abstract: An adjusting device for a vehicle seat is provided, the adjusting device may include, comprising: a first element; a second element having guide slots; and guide bolts, each of which being fixedly connected with the first element, slidably engaging one of the guide slots such that the second element is adjustable relative to the first element, and securing the second element to the first element; wherein the guide slots are engaged by the guide bolts and at least one other component.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 20, 2021
    Assignee: Brose Fahrzeugteile GmbH & Co. Kommanditgesellschaft, Coburg
    Inventors: Raymond Weir, Guiying Cui
  • ADJUSTING DEVICE FOR A VEHICLE SEAT
    Publication number: 20200247277
    Abstract: An adjusting device for a vehicle seat is provided, the adjusting device may include, comprising: a first element; a second element having guide slots; and guide bolts, each of which being fixedly connected with the first element, slidably engaging one of the guide slots such that the second element is adjustable relative to the first element, and securing the second element to the first element; wherein the guide slots are engaged by the guide bolts and at least one other component.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 6, 2020
    Inventors: Raymond WEIR, Guiying CUI
  • 2-amino-N'-benzylideneacetohydrazides and Derivatives for the Management of CFTR Protein Mediated Diseases
    Publication number: 20200138752
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Application
    Filed: January 3, 2020
    Publication date: May 7, 2020
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide Compounds for the Management of CFTR Protein Mediated Diseases
    Publication number: 20200085796
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Inventors: Nael McCarty, Guiying Cui
  • 2-amino-N?-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
    Patent number: 10555918
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: February 11, 2020
    Assignees: Emory University, Bar-Ilan University, Childern's Healthccare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
    Patent number: 10512636
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxa-diazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: December 24, 2019
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Nael McCarty, Guiying Cui
  • 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide Compounds for the Management of CFTR Protein Mediated Diseases
    Publication number: 20180147190
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxa-diazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 31, 2018
    Inventors: Nael McCarty, Guiying Cui
  • 2-amino-N'-benzylideneacetohydrazides and Derivatives for the Management of CFTR Protein Mediated Diseases
    Publication number: 20180147164
    Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 2-amino-N?-benzylidene-acetohydrazide compound or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N-benzylidene-acetohydrazide compound is ((E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(m-tolylamino)acetohydrazide; or (E)-N?-(3,5-dibromo-2,4-dihydroxybenzylidene)-2-(p-tolylamino)acetohydrazide.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 31, 2018
    Inventors: Nael McCarty, Guiying Cui, Hanoch Senderowitz, Netaly Khazanov